"Diabesity"-Obesity and type 2 diabetes (Update 2019)

被引:30
|
作者
Toplak, Hermann [1 ]
Leitner, Deborah Raphaela [2 ]
Harreiter, Juergen [3 ]
Hoppichler, Friedrich [4 ]
Wascher, Thomas C. [5 ]
Schindler, Karin [6 ]
Ludvik, Bernhard [7 ]
机构
[1] Med Univ Graz, Univ Klin Innere Med, Klin Abt Endokrinol & Diabetol, Auenbruggerpl 15, A-8036 Graz, Austria
[2] Med Univ Graz, Univ Klin Innere Med, Graz, Austria
[3] Med Univ Wien, Univ Klin Innere Med 3, Gender Med Unit, Klin Abt Endokrinol & Stoffwechsel, Vienna, Austria
[4] Krankenhaus Barmherzigen Bruder Salzburg, Abt Innere Med, Salzburg, Austria
[5] Hanusch Hosp, Med Abt, Vienna, Austria
[6] Med Univ Wien, Univ Klin Innere Med 3, Vienna, Austria
[7] Krankenanstalt Rudolfstiftung Wien, Med Abt Diabetol Endokrinol & Nephrol, Vienna, Austria
关键词
Obesity; Type; 2; diabetes; Body compos?ition; Nutrition; Formula diets; CARDIOVASCULAR RISK-FACTORS; EASO POSITION STATEMENT; LIFE-STYLE INTERVENTION; BODY-MASS INDEX; WEIGHT-LOSS; EUROPEAN ASSOCIATION; BARIATRIC SURGERY; LOW-CARBOHYDRATE; OVERWEIGHT; HEALTH;
D O I
10.1007/s00508-018-1418-9
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
For several years obesity and type2 diabetes have been increasingly summarized under the name diabesity. This is due to the fact that in most cases obesity precedes diabetes and is the most important risk factor for the worldwide increase of type2 diabetes. The body mass index (BMI) is avery crude measure of body fatness in individuals. Even normal weight persons can have too much body fat in cases of alack of muscle mass (sarcopenia), which is why additional measurements of waist circumference and body fatness, e.g. bioimpedance analysis (BIA), are recommended. Lifestyle management including nutrition modification and increase in physical activity are important measures for the prevention and treatment of diabetes. Regarding the treatment of type2 diabetes, body weight is increasingly used as a secondary target parameter. The choice of anti-diabetic treatment and also concomitant treatment is increasingly influenced by body weight. The significance of anti-obesity medications in the treatment of type2 diabetes will have to be clarified by future studies with body weight as the primary endpoint. Bariatric surgery is at present indicated with aBMI >35kg/m(2) with concomitant risk factors, such as diabetes and can lead at least to partial diabetes remission but has to be incorporated into an appropriatelifelong care concept.
引用
收藏
页码:71 / 76
页数:6
相关论文
共 50 条
  • [1] Foreword: Diabesity: Type 2 Diabetes and Obesity
    Werner, Erika F.
    CLINICAL OBSTETRICS AND GYNECOLOGY, 2021, 64 (01): : 134 - 135
  • [2] Obesity and type 2 diabetes (Update 2023)
    Clodi, Martin
    Toplak, Hermann
    Resl, Michael
    Brix, Johanna
    Leitner, Deborah Raphaela
    Harreiter, Juergen
    Hoppichler, Friedrich
    Wascher, Thomas C.
    Schindler, Karin
    Ludvik, Bernhard
    WIENER KLINISCHE WOCHENSCHRIFT, 2023, 135 (SUPPL 1) : 91 - 97
  • [3] Gut check on diabesity: leveraging gut mechanisms for the treatment of type 2 diabetes and obesity
    Will, Sarah
    Hornigold, David C.
    Baker, David J.
    Coghlan, Matthew P.
    Mesquita, Malcolm
    Trevaskis, James L.
    Naylor, Jacqueline
    CURRENT OPINION IN PHARMACOLOGY, 2017, 37 : 10 - 15
  • [4] Update: Hypogonadotropic Hypogonadism in Type 2 Diabetes and Obesity
    Dandona, Paresh
    Dhindsa, Sandeep
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2011, 96 (09): : 2643 - 2651
  • [5] Liraglutide for Type 2 diabetes and obesity: a 2015 update
    Iepsen, Eva Winning
    Torekov, Signe Sorensen
    Holst, Jens Juul
    EXPERT REVIEW OF CARDIOVASCULAR THERAPY, 2015, 13 (07) : 753 - 767
  • [6] The genetic basis of obesity-associated type 2 diabetes (diabesity) in polygenic mouse models
    Joost, Hans-Georg
    Schuermann, Annette
    MAMMALIAN GENOME, 2014, 25 (9-10) : 401 - 412
  • [7] The genetic basis of obesity-associated type 2 diabetes (diabesity) in polygenic mouse models
    Hans-Georg Joost
    Annette Schürmann
    Mammalian Genome, 2014, 25 : 401 - 412
  • [8] Insulin therapy of type 2 diabetes mellitus (Update 2019)
    Lechleitner, Monika
    Clodi, Martin
    Abrahamian, Heidemarie
    Brath, Helmut
    Brix, Johanna
    Drexel, Heinz
    Fasching, Peter
    Foeger, Bernhard
    Francesconi, Claudia
    Froehlich-Reiterer, Elke
    Harreiter, Juergen
    Hofer, Sabine E.
    Hoppichler, Friedrich
    Huber, Joakim
    Kaser, Susanne
    Kautzky-Willer, Alexandra
    Ludvik, Bernhard
    Luger, Anton
    Mader, Julia K.
    Paulweber, Bernhard
    Pieber, Thomas
    Prager, Rudolf
    Rami-Merhar, Birgit
    Resl, Michael
    Riedl, Michaela
    Roden, Michael
    Saely, Christoph H.
    Schelkshorn, Christian
    Schernthaner, Guntram
    Sourij, Harald
    Stechemesser, Lars
    Stingl, Harald
    Toplak, Hermann
    Wascher, Thomas C.
    Weitgasser, Raimund
    Winhofer-Stoeckl, Yvonne
    Zlamal-Fortunat, Sandra
    WIENER KLINISCHE WOCHENSCHRIFT, 2019, 131 (Suppl 1) : 39 - 46
  • [9] Adipositas und Typ-2-Diabetes (Update 2023)Obesity and type 2 diabetes (Update 2023)
    Martin Clodi
    Hermann Toplak
    Michael Resl
    Johanna Brix
    Deborah Raphaela Leitner
    Jürgen Harreiter
    Friedrich Hoppichler
    Thomas C. Wascher
    Karin Schindler
    Bernhard Ludvik
    Wiener klinische Wochenschrift, 2023, 135 : 91 - 97
  • [10] An update on peptide-based therapies for type 2 diabetes and obesity
    Bailey, Clifford J.
    Flatt, Peter R.
    Conlon, J. Michael
    PEPTIDES, 2023, 161